Eli Lilly Collaboration Programs
Neurological and cardiometabolic disorders
Discovery/Pre-clinicalActive
Key Facts
Indication
Neurological and cardiometabolic disorders
Phase
Discovery/Pre-clinical
Status
Active
Company
About ProQR Therapeutics
ProQR Therapeutics is a clinical-stage biotech pioneering a novel RNA base editing platform called Axiomer. The company leverages the body's own ADAR enzyme machinery to correct RNA sequences, aiming to treat genetic disorders that are currently untreatable. Its pipeline includes both internal programs and a significant partnership with Eli Lilly, targeting a range of severe diseases. ProQR is a public company, driven by a patient-focused mission and led by a founder-CEO with a personal connection to rare disease.
View full company profile